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Abstract 
Haloxylon salicornicum (H. salicornicum) is a plant that is frequently taken as a tea 
by Bedouin women in Egypt who are experiencing difficulties during pregnancy, as 
well as to provide relief from dysmenorrhoea.  Despite its medical use, there has 
been no detailed evaluation of the effect of this plant on uterine tissue.  Therefore, 
the initial aim of this study was to determine whether H. salicornicum affected the 
contraction of the mouse uterus in vitro.  The crude aqueous extract of H. 
salicornicum was found to inhibit the spontaneous contractions of the uterus, with the 
effect being rapid in onset and completely reversible upon washout.  Subsequent 
purification of the plant extract resulted in the identification of synephrine and N-
methyltyramine, both of which were found to have inhibitory effects on the 
spontaneous contractions of the uterus.  The EC50 for the purified constituent 
identified as synephrine was 0.82 ± 0.24 Pg/ml.  The inhibitory activity of crude H. 
salicornicum, as well as the isolated constituents, could be prevented by pre-
treatment of the uterus with the E-adrenoceptor antagonist propranolol.  In 
conclusion, the use of H. salicornicum during pre-term labour appears to be justified 
and its pharmacologic effect is consistent with it acting as a E-adrenoceptor agonist. 
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Introduction 
Regulation of the contractile status of the uterus is of fundamental importance for a 
successful outcome in pregnancy.  Throughout gestation the uterus has to remain 
relatively quiescent in order to prevent abortion, while at the end of the gestation 
period it has to produce the regular forceful uterine contractions that are required to 
bring about parturition [1, 2, 3].  If the uterus starts to contract too early, this will lead 
to premature birth, which is the most important single determinant of adverse 
neonatal outcome; both in terms of survival and quality of life.  In 2010, it was 
estimated that worldwide, 14.9 million babies (11.1% of all live births) were born 
preterm (<37 weeks of completed gestation) [4].  There is considerable variation 
between different regions throughout the world; for instance, the estimated preterm 
birth rate in developed regions is 8.6% while in sub-Saharan Africa it is 12.3% [4].  
Furthermore, in sub-Saharan Africa 28% of neonatal deaths are due entirely to their 
premature delivery [5], compared with 4-5% of the neonatal deaths in developed 
countries.  Unfortunately, maternal deaths during pregnancy are also significantly 
higher in sub-Saharan regions than they are in developed regions [6]. 
 
For women who are in preterm labour, a wide variety of pharmacological agents 
have been utilised to suppress uterine contractions (so-called tocolytics) [7].  
Tocolytics that are in current clinical use include: E2 adrenergic receptor agonists, 
calcium channel blockers, magnesium sulphate (MgSO4), nitrates, prostaglandin 
synthetase inhibitors, and oxytocin receptor antagonists [8, 9].  These tocolytics all 
have different mechanisms of action and a number of adverse effects associated 
with them, which need to be taken into account when considering which drug to use.  
While there is no standard first line drug that is universally used, a recent meta-
analysis study has indicated that calcium channel blockers and prostaglandin 
inhibitors have the highest probability of delaying delivery and improving neonatal 
outcomes [9].  Magnesium sulphate remains popular as a tocolytic in the USA and 
some other parts of the world; however, it is rarely used for this indication in the UK. 
 
In developing countries, there is often a reliance on traditional medicines to treat 
medical conditions.  Indeed, a number of clinically effective tocolytics have been 
derived from plant sources [10], and herbals are often used in the treatment of 
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painful menstrual cramps that are of uterine origin (dysmenorrhea) [11].  The 
Bedouin women of Egypt rely mainly on traditional medicine and one of the herbals 
that they are known to use during pregnancy and in the relief of dysmenorrhea is the 
plant Haloxylon salicornicum (Moq). Bunge ex Boiss (H. salicornicum).  During 
interviews with Bedouin women in St. Catherines, Egypt, it was revealed that when 
used for these purposes, the plant is taken as a tea 3-4 times per day [12]. 
 
H. salicornicum belongs to the Chenopodiaceae family and it is widely distributed in 
Northern Africa and Asia, in both temperate and tropical regions [13, 14], where it 
grows in sandy and stony desert areas as a diffuse shrub [15].  H. salicornicum is 
known to contain a number of alkaloids, including piperidyl alkaloid [16], haloxynine, 
and haloxine [17].  In addition it also contains pyranones [18], tannins, saponins, as 
well as a number of glycosides [14]. 
 
Although H. salicornicum is used by Bedouin women as a herbal medicine, to 
alleviate a number of obstetric and gynaecological problems, there has been no 
systematic study into its actual pharmacology [12].  Therefore, the initial aim of this 
study was to establish whether the crude extract of H. salicornicum, obtained from 
the same parts of the plant that are used by Bedouin women, had any effect on the 
contractility of the mouse uterus.  Thereafter, subsequent investigations were 
directed towards identifying the active constituent(s) in H. salicornicum as well as 
their mechanism of action on the uterus. 
 
 
Materials and methods 
Extraction and purification 
Plant material 
H. salicornicum was collected from Saint Catherine in the South Sinai peninsula, 
Egypt, and dried by a traditional technique that is utilised by Bedouin women.  
Specifically, the aerial parts of the plants were collected and placed on rocks in 
shaded areas to dry.  Two-three days later, the dried plants were collected and 
ground to a powder using a mortar and pestle.  Thereafter, the plant material (320 g) 
was extracted using a Soxhlet extractor with a methanol and water mixture (1:1 v/v).  
After evaporation of the methanol, the extract was freeze dried.  
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Phytochemical screening  
The freeze dried extract (18 g) was re-dissolved in 100 ml water and was partitioned 
by adding 250 ml chloroform.  The organic phase was dried over anhydrous sodium 
sulphate, filtered and evaporated to dryness at 40oC under vacuum using a rotary 
evaporator (Büchi R-205, Oldham, UK).  The dried extract was then dissolved in 
methanol and applied to a Sephadex® LH 20 column with bead size 25- ȝP 
(Sigma-Aldrich, UK) and eluted with methanol to obtain 30 fractions, which were 100 
ml each.  Fractions 1-15 were identical on thin later chromatography (TLC) with 
methanol-ethyl acetate (20:80 v/v), and were therefore combined to obtain sub-
fraction (A).  Similarly, fractions 16-30 were combined to obtain sub-fraction (B).  
Sub-fraction (B) was then subjected to C-18 silica gel column chromatography 
(Phenomenex, Macclesfield, UK) and elution with water/methanol to obtain 32 
fractions.  Sub-fraction (C) was made up of collected fractions 1-16, while sub-
fraction (D) was made up of fractions 17-32, after TLC analysis had indicated that 
these collected fractions were identical.  Approximately 500 mg of dried sub-fraction 
(D) was chromatographed by medium pressure liquid chromatography (MPLC) 
utilising a gradient of EtOAc and MeOH from 100:0 to 90:10 at a flow rate of 20 
ml/min for 50 min.  This yielded 200 fractions of 5 ml each.  The eluted fractions, 
which were deemed to be identical by TLC analysis, were pooled to yield HS1, HS2, 
HS3 and HS4.  NMR studies (1D and 2D) as well as liquid chromatography±mass 
spectrometry (LC-MS) were carried out to elucidate the structures of the compounds 
and fractions that were isolated. 
 
Animals 
Adult virgin female C57BL/6 mice (20-30 g) were used in this study.  The mice were 
humanely killed by cervical dislocation and all studies were performed in accordance 
with the guidelines and principles for the care and use of laboratory animals at the 
University of Strathclyde. 
 
Tissue preparation and organ bath 
Following a longitudinal midline incision, the uterus was carefully removed and 
immediately immersed in cold physiological saline solution (PSS) comprising (in 
mM): NaCl 118.4; KCl 4.7; MgSO4 1.2; glucose 11; CaCl2 2.5, NaHCO3 25, KH2PO4 
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1.2 and gassed with 95% O2-5% CO2.  The uterus was then placed in a Sylgard® 
coated dissecting dish containing cold PSS and the right and left uterine horns were 
carefully separated, with the aid of a dissecting microscope.  The right and left 
uterine horns were mounted vertically in 10 ml organ baths, one end being fixed to a 
stainless steel gas bubbler and the other end connected to a force displacement 
transducer (Grass FT03, Astro-Med, Slough, UK) using silk thread.  The output from 
the transducer was amplified by a Powerlab 4/35 and the data recorded on a 
personal computer running LabChart v7 software (ADInstruments Ltd., Oxford, UK).  
A resting tension of 0.5 g was applied and the uteri were allowed to contract 
spontaneously during an initial equilibration period of 30-60 min, before commencing 
any experimental protocol.  All experiments were carried out at 37oC and the PSS 
was continuously gassed with 95% O2-5% CO2. 
 
Effect of the crude aqueous extract of H. salicornicum, and its isolated 
constituents, on spontaneous contractions of the mouse uterus 
Following the initial equilibration period, either the crude aqueous extract or one of 
the H. salicornicum fractions was applied to the tissue.  All substances were 
dissolved in 10% (v/v) aqueous DMSO and were applied either as a single addition 
followed by washout, or in a cumulative manner (0.1-3 Pg/ml).  Whilst 10 min 
intervals were allowed between subsequent applications when the additions were 
cumulative, the effect had normally reached steady state well within the 10 min 
period.  In parallel control experiments, the effect of the vehicle (aqueous DMSO) on 
the contraction of the uterus was also examined. 
 
Effect of propranolol on the inhibitory action of H. salicornicum, and its 
isolated constituents 
After obtaining inhibition of the spontaneous uterine contractions with either the 
crude aqueous extract or H. salicornicum or one of its isolated constituents, the 
tissue was washed with fresh PSS and the spontaneous contractions were allowed 
to recover.  The non-selective E-antagonist propranolol (20 µM) was then applied to 
the tissue and following a 10 min equilibration period, the effect of crude H. 
salicornicum (3 Pg/ml) or its isolated constituents were then re-examined in the 
continued presence of propranolol. 
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Effect of H. salicornicum, and its isolated constituents, on KCl-induced 
contraction of the mouse uterus 
The uterus was initially contracted by the application of KCl (60 mM) and after the 
contractile response was stable, either the crude aqueous extract or H. salicornicum 
or one of its isolated constituents was added to the tissue in a cumulative manner 
(0.1-3 Pg/ml).  In some experiments H. salicornicum or one of its isolated 
constituents was added as a single concentration (3 Pg/ml). 
 
Chemicals 
Propranolol and (±) synephrine (both from Sigma-Aldrich, Gillingham, UK) were each 
prepared as 100 mM stock solutions in Milli-Q water, and subsequent dilutions were 
made using physiological salt solution.  Dimethyl sulphoxide (DMSO) and methanol 
(HPLC grade) were obtained from Sigma-Aldrich, UK.  All other reagents used were 
from BDH (VWR, Lutterworth, UK) and were of AnalaR grade. 
 
Data analysis 
Measurement of the spontaneous contractile activity was carried out by calculating 
the integral (area under the curve) of the contraction-time record using the LabChart 
software.  The integrated contractile response for the 6 min period preceding the 
addition of any substance served as a control, whilst a similar 6 min period during 
application of the substance was used to examine its effect.  The data was then 
expressed as a percentage of the integrated contractile response prior to any 
substance being applied (i.e. percentage of the control).  The frequency and 
amplitude of the contractile responses during the period that was integrated were 
also determined, and expressed as a percentage of the control prior to any addition.  
 
The data are shown as the mean ± s.e.m. and n is the number of uteri from different 
animals.  EC50 values for the isolated constituents were calculated by fitting the data 
for the contractile integral to the Hill equation.  One-way analysis of variance with 
'XQQHWW¶V SRVW KRF WHVW ZDV XVHG WR FRPSDUH WKH WUHDWPHQW WR WKH control group 
(GraphPad Prism v4) and P<0.05 was considered to be statistically significant. 
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Results 
Isolation and identification of the active compounds in H. salicornicum 
Four compounds HS1, HS2, HS3 and HS4 were isolated and characterized from 
sub-fraction (D) of H. salicornicum.  These compounds were identified as synephrine 
(HS1) and a mixture of synephrine and N-methyltyramine (HS2) by NMR 
spectroscopic, LC-MS analysis and comparison with previously published data [19].  
HS2, which was actually a mixture of N-methyltyramine and synephrine, had a molar 
ratio of 1.6:1 (based upon the integrals of the aromatic AA'BB' signals with the 
deshielded multiplets at GH 7.19 and GH 7.31 or the N-methyls at GH 2.69 and GH 2.77 
respectively).  The other purified constituents were identified as piperidine (HS3) and 
allantoin (HS4) [20].  Neither HS3 nor HS4 were found to have any effect on mouse 
uterine contractility and were therefore not investigated any further during this study. 
 
Effect of the crude extract of H. salicornicum on the spontaneous contractions 
of the mouse uterus 
The crude aqueous extract of H. salicornicum, decreased the spontaneous 
contractions of the mouse uterus in a concentration-dependent manner.  At the 
highest concentration examined (3 Pg/ml), the crude extract almost completely 
abolished the contractions (Figure 1).  The inhibitory effect of the crude extract was 
evident immediately upon application and was maintained for as long as the extract 
was present in the organ bath.  Upon washout of the extract, the inhibitory effect was 
readily reversed, and the effect could be consistently reproduced on subsequent re-
addition of the extract.  The vehicle alone (aqueous DMSO), which was used in this 
and subsequent studies involving the isolated constituents, had no effect on the 
spontaneous contractions of the mouse uterus. 
 
Effect of HS1 on the spontaneous contractions of the mouse uterus 
The purified constituent of H. salicornicum, HS1 (0.1-3 Pg/ml), inhibited the 
spontaneous contraction of the mouse uterus in a concentration-dependent manner 
(Figure 2).  As assessed by the integral of the contraction-time record, 0.5 Pg/ml HS1 
significantly decreased the contractile response by 44 ± 9% Q  Sޒ), when 
compared to control (Figure 3A).  This decrease in spontaneous contractility was due 
to a significant decrease in both the frequency and amplitude of the contractions, by 
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43 ± 9% (P<0.01) and by 42 ± 11% (P<0.01) respectively (Figure 3B and 3C).  
Increasing the concentration of HS1 to 1 Pg/ml resulted in the contractile response 
being reduced by 73 ± 5% of the control (P<0.01), with further decreases in the 
frequency and amplitude as well.  HS1 (1 Pg/ml) decreased the frequency of the 
spontaneous contractions by 62 ± 14% (P<0.01) and the amplitude by 77 ± 8% 
(P<0.01).  The highest concentration of HS1 examined (3 Pg/ml) completely 
abolished the spontaneous contractions in three out of the five tissue preparations.  
The EC50 for HS1 was 0.82 ± 0.24 Pg/ml (Figure 3) and its inhibitory effect was fully 
reversed within minutes, when the tissue was washed with fresh PSS. 
 
Effect of synephrine on spontaneous contractions of the mouse uterus 
Since HS1 was identified by NMR spectroscopy as synephrine, the effect of 
commercially supplied synephrine on uterine contractility was examined to confirm 
that these two substances had similar effects.  Synephrine also inhibited the 
spontaneous contractions of the mouse uterus in a concentration-dependent manner 
and the EC50 was 0.34 ± 0.16 Pg/ml (n=4, Figure 4A).  In the presence of 0.5 Pg/ml 
synephrine, the integral of the contraction was significantly reduced by 65 ± 11% of 
the control (P<0.01), with the amplitude and frequency decreasing by 38 ± 14% and 
49 ± 1% respectively (Figure 4B and 4C).  The spontaneous contractions were 
abolished in three out of four preparations with 1 Pg/ml synephrine and in all 
preparations when the concentration was increased to 3 Pg/ml. 
 
Effect of HS2 on spontaneous contractions of the mouse uterus 
Application of HS2 (0.1-3 Pg/ml) also inhibited spontaneous contractions of the 
mouse uterus in a concentration-dependent manner, yielding an EC50 0.62 ± 0.31 
Pg/ml (n=3, Figure 5A).  HS2 (1 Pg/ml) significantly inhibited the spontaneous 
contractions of the uterus by 66 ± 7% (P<0.05) when compared to the control.  The 
same concentration of HS2 decreased both the amplitude and frequency of the 
spontaneous contractions by 50 ± 7% and 86 ± 5% (P<0.05) respectively (Figure 5B 
and 5C)  Increasing to concentration of HS2 to 3 Pg/ml completely abolished the 
spontaneous contractions in two out of the three tissue preparations. 
 
Effect of propranolol on the inhibitory action of HS1, synephrine and HS2  
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The non-VHOHFWLYH ȕ-adrenoceptor antagonist propranolol (20 µM), by itself, was 
found to have no effect on the spontaneous contractility of the uterus.  The integral of 
the contraction-time record was 98 ± 1% of the control obtained in the absence of 
propranolol (Figure 6).  When HS1 (3 Pg/ml) was added in the presence of 
propranolol, the inhibitory effect normally seen was largely prevented.  HS1 still 
caused a small reduction in contractility, by 10 ± 2% from the control; but this ZDVQ¶W
significantly different from the effect of propranolol alone.  The inhibitory effect of the 
commercially obtained synephrine was also prevented by propranolol, with 
synephrine only reducing the spontaneous contractions by 6 ± 2%.  Although HS2 (3 
Pg/ml) was still capable of producing a small reduction in spontaneous contractility 
(by 12 ± 3% of the control) in the presence of propranolol, it was also much less than 
that previously observed in the absence of propranolol. 
 
Effect of HS1 on uterine contractions induced by depolarization 
Application of KCl (60 mM) to the uterus produced a biphasic contraction; comprising 
an initial transient contraction followed by a relatively sustained plateau.  When HS1 
(1-3 Pg/ml) was applied during the sustained phase of the contraction, it caused a 
concentration dependent relaxation, with complete relaxation to baseline tension 
being achieved with the highest concentration of HS1 examined (3 Pg/ml) (Figure 7).  
 
 
Discussion 
The crude extract of H. salicornicum was found to have an inhibitory effect on the 
spontaneous contractions of the mouse uterus, which was rapid in onset and fully 
reversible upon washout.  Purification of the extracts obtained from H. salicornicum, 
resulted in the identification of HS1 (synephrine) and HS2 (a mixture of synephrine 
and N-methyltyramine), which were subsequently shown to be responsible for the 
inhibitory effect of this plant on the contractions of the mouse uterus.  Furthermore, 
the effects of HS1 and HS2 were concentration-dependent and were mediated by 
the activation of E-adrenoceptors, since their inhibitory action could be prevented by 
prior treatment of the uterus with propranolol. 
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It has long been known that stimulation of E-adrenoceptors is responsible for smooth 
muscle relaxation in many organs including the uterus [21, 22].  Studies on the 
responsiveness of the uterus to E-adrenoceptor agonists, as well as characterisation 
of myometrial E-adrenergic binding sites in several species (human, rat, and guinea-
pig), have indicated that E2 is the dominant subtype present in this tissue [23, 24, 
25].  E2-adrenoceptor agonists are known to inhibit contraction of the uterus by 
stimulating the production of cAMP [26].  They are effective in delaying delivery for 
up to 48 hours and have no effect on perinatal mortality or morbidity [27].  At the end 
of pregnancy the expression of E2-adrenoceptors in the uterus has been reported to 
either decrease [24] or remain unchanged [28].  Certainly in humans, as well as in 
rodents, the E-adrenoceptor signalling pathway desensitizes at the end of 
pregnancy, thereby contributing to the initiation of contractions at parturition [29, 30].  
There is also a loss of responsiveness of the uterus to E-adrenoceptor agonists 
following long term exposure to these drugs [31].  These factors are likely to underlie 
the reason why E-adrenoceptor agonists become less effective tocolytics at the end 
of pregnancy.  The most widely reported adverse effects of therapeutic doses of E2-
adrenoceptor agonists are skeletal muscle tremor [22] cardiac effects [32]; which 
does cause some limitations in their clinical use as tocolytics. 
 
Phenolic amines, which include synephrine, are a class of secondary metabolites 
found in citrus fruits [33] and other edible plants that have been reported to have a 
wide range of health promoting activities [34, 35].  Synephrine is used as a 
sympathomimetic agent [35], and its structural isomer neo-synephrine 
(phenylephrine) is used in the treatment of common colds.  Recently, synephrine has 
received increasing attention as results from several studies, including human trials 
[36], have suggested that it has promise as an aid to weight management and 
obesity reduction [35].  Synephrine is also known to be capable of causing 
vasoconstriction, through the activation of D-adrenoceptors [37], which would 
obviously be considered as undesirable action of this substance.  
 
The commercially supplied synephrine produced a very similar inhibitory effect on 
the mouse uterus to that obtained with HS1.  Although the commercial variant 
appeared slightly more potent than the purified HS1, there was no significant 
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difference in the EC50 values, and the slight difference could simply be due to the 
commercial variant being of higher purity.  The effect of HS1 and synephrine on the 
spontaneous contractions of the mouse uterus was to reduce both their frequency 
and amplitude, which accounts for the concentration-dependent decrease in the 
contractile integral.  Further support that HS1 is synephrine, was provided by the 
finding that the non-specific E-adrenoceptor antagonist, propranolol could block the 
effect of both these substances.  HS1 was also effective in causing relaxation of the 
mouse uterus, which had been pre-contracted by KCl-induced depolarisation of the 
smooth muscle. 
 
N-Methyltyramine has been found to occur in a wide variety of plants [38] including 
H. salicornicum [39, 40].  Like synephrine, N-methyltyramine is a constituent of bitter 
orange [41].  N-Methyltyramine is thought to act by the same mechanism as 
tyramine, that is, as an indirect sympathomimetic due to its ability to cause the 
release of noradrenaline from adrenergic varicosities [42].  This would explain why 
HS2 also had an inhibitory effect on the spontaneous contractions of the mouse 
uterus and why propranolol was able to block its inhibitory effect.  N-Methyltyramine 
has previously been shown to increase blood pressure in anesthetized rats, and to 
increase both the intensity and rate of contraction of guinea pig right atrium by 
inducing the release of norepineprine [43].  Such a mechanism is consistent with 
what is being proposed here for the effect of N-methyltyramine on the uterus. 
 
Knowing the pharmacology of HS1 and HS2, it might be expected that Bedouin 
women who are using H. salicornicum would experience an increase in their blood 
pressure; however this does not appear to be an issue (Dr. Mohamed Fawzy, 
General Practitioner in the St. Catherine Protected Area, personal communication).  
One possible reason ZK\ WKLV LVQ¶W D VLJQLILFDQW SURElem is that since the crude 
extract contains other chemical substances, some of these other constituents may 
counteract the effects of HS1 and HS2.  Such a notion is supported by preliminary 
studies with fraction C, which was found to be capable of causing relaxation of the 
mouse aorta pre-contracted with phenylephrine.  Thus, the overall pharmacological 
effect of H. salicornicum is going to depend upon what other biologically active 
substances are present in it. 
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Conclusion 
This study has provided credible evidence to support the use of H. salicornicum by 
indigenous groups, such as the Bedouin women of Egypt, where conventional 
medical care is often unavailable and the management of premature birth still 
remains unsatisfactory [12].  Abnormal contraction of the uterus can lead to 
premature delivery of the foetus and it is known to be a significant cause of prenatal 
morbidity and mortality [44].  The inhibitory action of H. salicornicum on uterine 
contractility, shown in the current study, means that it is likely to be effective as a 
tocolytic.  The active constituents in H. salicornicum were found to be synephrine 
and N-methyltyramine and they both exert their effects ultimately through the 
activation of E-adrenoceptors on uterine smooth muscle.  In summary, H. 
salicornicum is a natural product with biological activity and this study provides 
pharmacological evidence supporting the traditional medicinal use of this plant 
among Bedouin communities for the treatment of perinatal problems. 
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Figure 1.  Effect of the crude extract of H. salicornicum on the spontaneous 
contractions of the mouse uterus.  Representative recording showing the effect of 
the crude aqueous extract of H. salicornicum (3 Pg/ml) on the spontaneous 
contractions of the mouse uterus.  The inhibitory effect of the extract was rapid in 
onset and could be completely reversed upon washout. 
 
Figure 2.  Effect of HS1 on the spontaneous contractions of the mouse uterus.  
Representative recordings showing the effect of HS1 (1 and 3 Pg/ml) on the 
spontaneous contractions of the mouse uterus.  HS1 was one of the constituents 
purified from H. salicornicum and found to have an inhibitory effect on uterine 
contractions.  All recordings are from the same mouse uterus and are shown in 
discontinuous form for clarity. 
 
Figure 3.  Effect of HS1 on the spontaneous contractions of the mouse uterus. 
(A) Concentration response curve examining the effect of HS1 on spontaneous 
contractions of the mouse uterus.  The data represents the integral of the 
contraction-time record and is expressed as a percentage of the control response in 
the absence of HS1.  The curve has been fitted to the Hill equation.  The effect of 
HS1 on the amplitude (B) and frequency (C) of the spontaneous contractions is also 
shown.  The data is presented as mean ± s.e.m and n=5.  ** indicates P<0.01 HS1 
treatment vs. control. 
 
Figure 4.  Effect of synephrine on the spontaneous contractions of the mouse 
uterus. (A) Concentration response curve examining the effect of synephrine on 
spontaneous contractions of the mouse uterus.  The data represents the integral of 
the contraction-time record and is expressed as a percentage of the control 
response in the absence of synephrine.  The curve has been fitted to the Hill 
equation and the HS1 data from Figure 3 is included for comparison.  The effect of 
synephrine on the amplitude (B) and frequency (C) of the spontaneous contractions 
is also shown.  The data is presented as mean ± s.e.m and n=4.  ** indicates P<0.01 
synephrine treatment vs. control. 
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Figure 5.  Effect of HS2 on the spontaneous contractions of the mouse uterus. 
(A) Concentration response curve examining the effect of HS2 on spontaneous 
contractions of the mouse uterus.  The data represents the integral of the 
contraction-time record and is expressed as a percentage of the control response in 
the absence of HS2.  The curve has been fitted to the Hill equation.  The effect of 
HS2 on the amplitude (B) and frequency (C) of the spontaneous contractions is also 
shown.  The data is presented as mean ± s.e.m and n=3.  ** indicates P<0.01 HS2 
treatment vs. control. 
 
Figure 6.  Effect of propranolol on the inhibitory action of HS1 and HS2.  (A) 
Representative recording showing spontaneous contractions of the mouse uterus 
and how they are unaffected by the non-selective E-antagonist propranolol (20 µM).  
In the presence of propranolol the inhibitory action of HS1 (3 Pg/ml) was largely 
prevented.  All recordings are from the same mouse uterus.  (B) Summary data 
showing how propranolol affects the inhibitory action of HS1, synephrine and HS2 
(all at 3 Pg/ml on the mouse uterus.  The data represents the integral of the 
contraction-time record and is expressed as a percentage of the control response in 
the absence of propranolol.  The data is presented as mean ± s.e.m and n=3.  ** 
indicates P<0.01 for HS2 vs. propranolol alone. 
 
Figure 7.  Effect of HS1 on KCl-induced contraction of the mouse uterus.  
Representative recording showing the inhibitory action of HS1 (1 and 3 Pg/ml) on the 
mouse uterus that had been pre-contracted with KCl (60 mM).  This figure is 
representative of 3 similar independent experiments. 
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